3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Infections
1
Hematologic Neoplasms
1
Agammaglobulinemia
1
Interventions
Cisplatin
22
pembrolizumab
17
Drug Therapy
16
Carboplatin
15
Paclitaxel
12
Dexamethasone
12
Gemcitabine
11
Magnetic Resonance Spectroscopy
10
Bevacizumab
10
Docetaxel
9
venetoclax
8
atezolizumab
8
Pemetrexed
8
Oxaliplatin
8
Specimen Handling
7
Radiotherapy
7
Nivolumab
7
Cyclophosphamide
7
Capecitabine
7
Methotrexate
6
130-nm albumin-bound paclitaxel
6
durvalumab
5
blinatumomab
5
Cytarabine
5
Androgen Antagonists
5
tislelizumab
4
spartalizumab
4
pertuzumab
4
Vincristine
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Recruiting
×
Clavulanic Acid
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled